Activity of Protein S-C4b Binding Protein and Total TFPI Levels in Egyptian SLE Patients: A Cross-Sectional Study

Wafaa M. Abdelghany; Mona Salah; Walaa Abdelrahman Saleh; Ola M. Dahy; Rehab Helmy

doi:10.3889/oamjms.2022.8247

Authors

Wafaa M. Abdelghany Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt https://orcid.org/0000-0001-6072-1318
Mona Salah Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Walaa Abdelrahman Saleh Department of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Cairo, Egypt
Ola Mohsen Dahy Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Rehab Helmy Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2022.8247

Keywords:

SLE, Protein S, C4BP, TFPI, Thrombosis

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is an immune disorder with alternating active and remission phases. Cardiovascular diseases and thrombosis are the major causes of mortality in SLE. The anticoagulant activity of Protein S (PS) is complemented by C4 binding protein (C4BP) and tissue factor pathway inhibitor (TFPI).

AIM: This study aims to determine the extent of change in the levels of PS activity, C4BP, and total TFPI in active SLE in comparison to the SLE remission phase and their association with thrombosis during SLE flare.

METHODS: The study included 180 Egyptian SLE patients who were classified into two groups: 100 SLE cases as the active group and 80 SLE cases as the remission group. The PS activity levels were processed on automated coagulation analyzers, whereas the C4BP and total TFPI levels were measured via enzyme-linked immunosorbent assay.

RESULTS: The PS activity and C4BP levels were lower in the active SLE cases than in the remitted ones (p < 0.05). The levels of PS activity and C4BP were revealed to be independent predictors of SELENA-SLEDAI flare scores. In active SLE cases, the PS activity and C4BP levels were rated as excellent and fair classifiers of thrombotic risk in SLE flare, respectively. The total TFPI levels showed no association with SLE activity or its thrombotic consequences.

CONCLUSIONS: The levels of PS activity and C4BP act as important biomarkers for SLE activity. Both can be implanted as predictive tools for thrombosis during activity.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Yen EY, Singh RR. Brief report: Lupus-an unrecognized leading cause of death in young females: A population-based study using nationwide death certificates, 2000-2015. Arthrit Rheumatol. 2018;70(8):1251-5. https://doi.org/10.1002/art.40512 PMid:29671279

Carter EE, Barr SG, Clarke AE. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. https://doi.org/10.1038/nrrheum.2016.137 PMid:27558659

Housey M, DeGuire P, Lyon-Callo S, Wang L, Marder W, McCune WJ, et al. Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: The Michigan Lupus Epidemiology and Surveillance Program. Am J Public Health. 2015;105(5):e74-9. https://doi.org/10.2105/AJPH.2014.302423 PMid:25790387

Margery-Muir A, Bundell C, Nelson D, Groth DM, Wetherall JD. Gender balance in patients with systemic lupus erythematosus. Autoimmun Rev. 2017;16(3):258-8. https://doi.org/10.1016/j.autrev.2017.01.007 PMid:28137478

El-Garf AK, Gheith RE, Badran SN. Clinical pattern in Egyptian systemic lupus erythematosus patients with pleuropulmonary involvement. Egypt Rheumatol. 2017;39(2):83-8.

Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2018;27(2):225-34. https://doi.org/10.1177/0961203317716787 PMid:28659045

Andrianova IA, Ponomareva AA, Mordakhanova ER, Le Minh G, Daminova AG, Nevzorova TA, et al. In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation. J Autoimmun. 2020;107:102355. https://doi.org/10.1016/j.jaut.2019.102355 PMid:31732191

Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol. 2016;7:55. https://doi.org/10.3389/fimmu.2016.00055 PMid:26941740

Ekdahl KN, Soveri I, Hilborn J, Fellström B, Nilsson B. Cardiovascular disease in haemodialysis: Role of the intravascular innate immune system. Nature reviews. Nephrology. 2017;13:285-96. https://doi.org/10.1038/nrneph.2017.17 PMid:28239169

Webb JH, Blom AM, Dahlbäck B. Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol. 2002;169(5):2580-6. https://doi.org/10.4049/jimmunol.169.5.2580 PMid:12193728

Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood. 2018;131(12):1360-1. https://doi.org/10.1182/blood-2017-09-800326 PMid:29317453

Zakai NA, Lutsey PL, Folsom AR, Heckbert SR, Cushman M. Total tissue factor pathway inhibitor and venous thrombosis. The longitudinal investigation of thromboembolism etiology. Thromb Haemost. 2010;104(2):207-12. https://doi.org/10.1160/TH09-10-0693 PMid:20431849

Mast AE. Tissue factor pathway inhibitor, multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 2016;36(1):9-14. https://doi.org/10.1161/ATVBAHA.115.305996 PMid:26603155

Sultan A, Malik IH. Recurrent cerebral infarctions in a young patient: Combined protein C and S deficiencies. J Coll Physicians Surg Pak. 2013;23(10):813-4. PMid:24169393

Sandhu V, Quan M. SLE and serum complement: Causative, concomitant or coincidental? Open Rheumatol J. 2017;11:113-22. https://doi.org/10.2174/1874312901711010113 PMid:29290848

Daha MR, Hazevoet HM, Hermans TJ, Vanes LA, Cats A. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus. Clin Exp Immunol. 1983;54(1):248-52. PMid:6604610

Meriam H, Soumaya B, Lamia R, Karim ZM. Acquired protein S deficiency in a patient with lupus nephritis. Saudi J Med Med Sci. 2019;7(1):51-2. https://doi.org/10.4103/sjmms.sjmms_22_17 PMid:30787859

Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: Diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017;28(1):4-12. https://doi.org/10.31138/mjr.28.1.4 PMid:32185248

Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthrit Rheum. 2012;64(8):2677-86. https://doi.org/10.1002/art.34473 PMid:22553077

Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-8. https://doi.org/10.1056/NEJMoa051135 PMid:16354891

Marlar RA, Gausman JN. Protein S abnormalities: A diagnostic nightmare. Am J Hematol. 2011;86(5):418-21. https://doi.org/10.1002/ajh.21992 PMid:21523802

Johnson NV, Khor B, Van Cott EM. Advances in laboratory testing for thrombophilia. Am J Hematol. 2012;87(S1):S108-12. https://doi.org/10.1002/ajh.23186 Mid:22473489

Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34- 45. https://doi.org/10.1038/nri3345 PMid:23222502

Zhang Y, Zhou Q, Zou Y, Song X, Xie S, Tan M, et al. Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: A prospective cohort study. J Thromb Thromb. 2016;41(4):619-27. https://doi.org/10.1007/s11239-015-1275-6 PMid:26370200

Han X, Zha H, Yang F, Guo B, Zhu B. Tumor-derived tissue factor aberrantly activates complement and facilitates lung tumor progression via recruitment of myeloid-derived suppressor cells. Int J Mol Sci. 2017;18(1):22. https://doi.org/10.3390/ijms18010022 PMid:28106852

Mohlin FC, Blom AM. Purification and functional characterization of C4b-binding protein (C4BP). Methods Mol Biol. 2014;1100:169-76. https://doi.org/10.1007/978-1-62703-724-2_14 PMid:24218259

Bertolaccini ML, Sanna G, Ralhan S, Gennari LC, Merrill JT, Khamashta MA, et al. Antibodies directed to protein S in patients with systemic lupus erythematosus: Prevalence and clinical significance. Thromb Haemost. 2003;90(4):636-41. https://doi.org/10.1160/TH03-03-0151 PMid:14515184

Song KS, Park YS, Kim HK. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 2000;43:557-60. https://doi.org/10.1002/1529-0131(200003)43:3<557:AID-ANR11>3.0.CO;2-O PMid:10728748

Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology (Oxford). 2005;44(10):1227-32. https://doi.org/10.1093/rheumatology/keh719 PMid:15972354

Qin L, Stanley S, Ding H, Zhang T, Truong V, Celhar T, et al. Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. Arthrit Res Ther. 2019;21(1):176. https://doi.org/10.1186/s13075-019-1959-y PMid:31319876

Jung JY, Kim HA, Lee HY, Suh CH. Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4-year follow-up study. Int J Rheumatic Dis. 2019;22(8):1410-8. https://doi.org/10.1111/1756-185X.13588 PMid:31050219

Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthrit Res Ther. 2010;12(4):R146. https://doi.org/10.1186/ar3088 PMid:20637106

Bergamaschini L, Miedico A, Cicardi M, Coppola R, Faioni EN, Agostoni A. Consumption of C4b-binding protein (C4BP) during in vivo activation of the classical complement pathway. Clin Exp Immunol. 1999;116(2):220-4. https://doi.org/10.1046/j.1365-2249.1999.00874.x PMid:10337010

Wenderfer SE, Soimo K, Wetsel RA, Braun MC. Analysis of C4 and the C4 binding protein in the MRL/lpr mouse. Arthrit Res Ther. 2007;9(5):R114. https://doi.org/10.1186/ar2320 PMid:17971229

Seriolo B, Accardo S, Garnero A, Fasciolo D, Cutolo M. Anticardiolipin antibodies, free protein S levels and thrombosis: A survey in a selected population of rheumatoid arthritis patients. Rheumatology. 1999;38(7):675-678. https://doi.org/10.1093/rheumatology/38.7.675 PMid:10461484

van der Meer JH, van der Poll T, van’t Veer C. TAM receptors, Gas6, and protein S: Roles in inflammation and hemostasis. Blood. 2014;123(16):2460-9. https://doi.org/10.1182/blood-2013-09-528752 PMid:24596417

Adams MJ, Donohoe S, Mackie IJ, Machin SJ. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol. 2001;114(2):375-9.